Difference between revisions of "Melanoma, KIT-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...")
 
Tag: visualeditor
Line 1: Line 1:
 
{| class="wikitable" style="text-align:center; width:50%;"
 
{| class="wikitable" style="text-align:center; width:50%;"
−
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
+
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editor'''
 
|-
 
|-
−
|style="background-color:#F0F0F0|[[File:Bethbuchbinder.jpg|frameless|upright=0.3|center]]
+
| style="background-color:#F0F0F0" |[[File:Bethbuchbinder.jpg|frameless|upright=0.3|center]]
 
|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Dana-Farber Cancer Institute<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn]
 
|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Dana-Farber Cancer Institute<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn]
 
|-
 
|-
Line 21: Line 21:
 
===Variant #1, pre-planned escalation {{#subobject:662612|Variant=1}}===
 
===Variant #1, pre-planned escalation {{#subobject:662612|Variant=1}}===
 
{| class="wikitable" style="width: 50%; text-align:center;"  
 
{| class="wikitable" style="width: 50%; text-align:center;"  
−
!style="width: 25%"|Study
+
! style="width: 25%" |Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ Hodi et al. 2013 (BUS255)]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ Hodi et al. 2013 (BUS255)]
−
|style="background-color:#91cf61"|Phase II
+
| style="background-color:#91cf61" |Phase II
 
|-
 
|-
 
|}
 
|}
−
''Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.''
+
'''Biomarker eligibility criteria'''
 +
 
 +
* Gene: KIT
 +
* Alteration: amplification and mutation
 +
* Acceptable methods of measurement: PCR or HPLC
 +
 
 
====Chemotherapy====
 
====Chemotherapy====
 +
 
*[[Imatinib (Gleevec)]] as follows:
 
*[[Imatinib (Gleevec)]] as follows:
 
**Starting dose: 400 mg PO once per day
 
**Starting dose: 400 mg PO once per day
Line 38: Line 44:
 
===Variant #2 {{#subobject:d1f61b|Variant=1}}===
 
===Variant #2 {{#subobject:d1f61b|Variant=1}}===
 
{| class="wikitable" style="width: 50%; text-align:center;"  
 
{| class="wikitable" style="width: 50%; text-align:center;"  
−
!style="width: 25%"|Study
+
! style="width: 25%" |Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ Carvajal et al. 2011]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ Carvajal et al. 2011]
−
|style="background-color:#91cf61"|Phase II
+
| style="background-color:#91cf61" |Phase II
 
|-
 
|-
 
|}
 
|}
 
''Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.''
 
''Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.''
 
====Chemotherapy====
 
====Chemotherapy====
 +
 
*[[Imatinib (Gleevec)]] 400 mg PO twice per day
 
*[[Imatinib (Gleevec)]] 400 mg PO twice per day
  
Line 52: Line 59:
  
 
===References===
 
===References===
−
# Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21642685 PubMed]
+
 
−
# '''BUS255:''' Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. [http://jco.ascopubs.org/content/31/26/3182.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23775962 PubMed]
+
#Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21642685 PubMed]
 +
#'''BUS255:''' Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. [http://jco.ascopubs.org/content/31/26/3182.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23775962 PubMed]
  
 
[[Category:Melanoma regimens]]
 
[[Category:Melanoma regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Skin cancers]]
 
[[Category:Skin cancers]]

Revision as of 23:29, 8 January 2020

Section editor
Bethbuchbinder.jpg
 Elizabeth Buchbinder, MD
Dana-Farber Cancer Institute
Boston, MA
LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main melanoma page for other regimens.

1 regimens on this page
2 variants on this page


Advanced or metastatic disease, TKI-naive

Imatinib monotherapy

back to top

Variant #1, pre-planned escalation

Study Evidence
Hodi et al. 2013 (BUS255) Phase II

Biomarker eligibility criteria

  • Gene: KIT
  • Alteration: amplification and mutation
  • Acceptable methods of measurement: PCR or HPLC

Chemotherapy

  • Imatinib (Gleevec) as follows:
    • Starting dose: 400 mg PO once per day
    • Upon progression: 400 mg PO twice per day

Continued indefinitely

Variant #2

Study Evidence
Carvajal et al. 2011 Phase II

Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.

Chemotherapy

Continued indefinitely

References

  1. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. contains protocol link to PMC article PubMed
  2. BUS255: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. link to original article contains verified protocol link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Melanoma,_KIT-mutated&oldid=41836"